13 documents

Read All
13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
Read More
02:28 , Mar 9, 2018 |  BC Innovations  |  Product R&D

Chips for tox

After several years’ pushing from FDA, NIH and DARPA for more predictive preclinical tox tests, organ-on-a-chip companies are close to demonstrating their models can detect signals missed in animals. While replacing animals is nowhere in...
Read More
01:19 , Feb 16, 2018 |  BC Innovations  |  Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
Read More
23:17 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Avidly specific

With its first two programs headed for the clinic next year, AvidBiotics Corp. is seeing the fruits of its move to human therapeutics from food safety and animal health. Using engineered peptides, the company has...
Read More
19:45 , Apr 21, 2017 |  BioCentury  |  Emerging Company Profile

Orchard’s pickings

Orchard Therapeutics Ltd. ’s autologous stem cell therapies could improve upon more advanced cell and gene therapies that also were designed to produce durable responses by restoring production of missing enzymes in rare genetic diseases....
Read More
07:00 , Aug 21, 2014 |  BC Innovations  |  Targets & Mechanisms

Corneal perspectives

Two independent findings could increase the availability of tissue for corneal transplants. A University of California, San Diego -led team has created a new source of limbal stem cells-which are needed for clear vision-by expressing...
Read More
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Cell Source, Cell Source deal

Cell Source Ltd. reverse-merged with Cell Source Inc. (formerly Ticket To See Inc.). Cell Source Ltd. shareholders own 78.5% of the combined company, while shareholders of Cell Source Inc. will own the remaining 21.5%. The...
Read More
07:00 , Jun 30, 2014 |  BioCentury  |  Product Development

Mending the majority

The much anticipated Phase III data for the combination of lumacaftor and Kalydeco ivacaftor from Vertex Pharmaceuticals Inc. didn't disappoint. Investors boosted the biotech's market cap by $6.4 billion, or 40%, on data that could...
Read More
08:00 , Nov 21, 2013 |  BC Innovations  |  Tools & Techniques

Naive human iPS cells

The inability to generate fully undifferentiated human induced pluripotent stem cells in vitro has dogged the development of stem cell-based platforms because the residual lineage bias of the cells most likely contributes to the inefficiency...
Read More
07:00 , Aug 1, 2013 |  BC Innovations  |  Tools & Techniques

The liver's new bud

Yokohama City University and Sekisui Medical Co. Ltd. researchers have produced vascularized human liver tissue that displays promising metabolic and regenerative capacity in mice. 1 The team now aims to scale up the procedure to...
Read More